Evaluation of Six Weekly Oral Fecal Microbiota Transplants in People with HIV.
HIV
fecal microbiota transplant
inflammation
microbiome
Journal
Pathogens & immunity
ISSN: 2469-2964
Titre abrégé: Pathog Immun
Pays: United States
ID NLM: 101683909
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
06
2020
accepted:
13
11
2020
entrez:
27
1
2021
pubmed:
28
1
2021
medline:
28
1
2021
Statut:
epublish
Résumé
Reduced microbiota diversity (dysbiosis) in people with HIV (PWH) likely contributes to inflammation, a driver of morbidity and mortality. We aimed to evaluate the safety and tolerability of 6 weekly oral fecal microbiota transplants (FMT) administered to reverse this dysbiosis. Six PWH on suppressive antiretroviral therapy (ART) received 6 weekly doses of lyophilized fecal microbiota product from healthy donors. Shotgun sequencing on stool before, after last FMT, and 20 weeks thereafter was performed. Inflammation and gut permeability biomarkers were measured. Median age at week 0 was 39 years, CD4 Weekly FMT was safe and well-tolerated. α diversity increased in participants with the lowest baseline α diversity during the treatment period. Future randomized, controlled trials of FMT should consider evaluating PWH with greater inflammation, gut damage, or dysbiosis as this population may be most likely to show a significant response.ClinicalTrials.gov Identifier: NCT03329560.
Sections du résumé
BACKGROUND
BACKGROUND
Reduced microbiota diversity (dysbiosis) in people with HIV (PWH) likely contributes to inflammation, a driver of morbidity and mortality. We aimed to evaluate the safety and tolerability of 6 weekly oral fecal microbiota transplants (FMT) administered to reverse this dysbiosis.
METHODS
METHODS
Six PWH on suppressive antiretroviral therapy (ART) received 6 weekly doses of lyophilized fecal microbiota product from healthy donors. Shotgun sequencing on stool before, after last FMT, and 20 weeks thereafter was performed. Inflammation and gut permeability biomarkers were measured.
RESULTS
RESULTS
Median age at week 0 was 39 years, CD4
CONCLUSIONS
CONCLUSIONS
Weekly FMT was safe and well-tolerated. α diversity increased in participants with the lowest baseline α diversity during the treatment period. Future randomized, controlled trials of FMT should consider evaluating PWH with greater inflammation, gut damage, or dysbiosis as this population may be most likely to show a significant response.ClinicalTrials.gov Identifier: NCT03329560.
Identifiants
pubmed: 33501400
doi: 10.20411/pai.v5i1.388
pii: pai.v5i1.388
pmc: PMC7815055
doi:
Banques de données
ClinicalTrials.gov
['NCT03329560']
Types de publication
Journal Article
Langues
eng
Pagination
364-381Informations de copyright
Copyright © Pathogens and Immunity 2020.
Déclaration de conflit d'intérêts
H.L.D. and Z-D.J. have applied for a patent for PRIM-DJ2727, and H.L.D. has received a grant from Rebiotix to study their FMT product. MF is an employee of Associates of Cape Cod, Inc., the manufacturer of the (1,3)-β-D-glucan test used in this study. No other authors have competing interests.
Références
J Infect Dis. 2000 May;181 Suppl 2:S254-61
pubmed: 10804134
Inflamm Bowel Dis. 2019 May 4;25(6):969-979
pubmed: 30852592
Bioinformatics. 2015 May 15;31(10):1674-6
pubmed: 25609793
EBioMedicine. 2016 Jan 28;5:135-46
pubmed: 27077120
Gastroenterology. 2017 Mar;152(4):799-811.e7
pubmed: 27866880
PLoS One. 2018 Nov 2;13(11):e0205064
pubmed: 30388112
Microbiome. 2018 Sep 18;6(1):166
pubmed: 30227892
J Infect Dis. 2011 Jul 1;204(1):154-63
pubmed: 21628670
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):722-7
pubmed: 26733683
Crit Rev Food Sci Nutr. 2019;59(sup1):S130-S152
pubmed: 30580556
J Infect Dis. 2020 Apr 27;221(10):1567-1570
pubmed: 31282534
Science. 2014 Aug 29;345(6200):1048-52
pubmed: 25170151
Med Mycol. 2014 Jul;52(5):455-61
pubmed: 24906361
Front Cell Infect Microbiol. 2019 Jan 21;9:2
pubmed: 30719428
J Infect Dis. 2014 Oct 15;210(8):1248-59
pubmed: 24795473
J Infect Dis. 2011 Mar 15;203(6):780-90
pubmed: 21252259
Appl Microbiol Biotechnol. 2017 Jan;101(1):47-64
pubmed: 27888332
Drug Saf. 2019 Jul;42(7):869-880
pubmed: 30972640
BMC Microbiol. 2016 Nov 16;16(1):275
pubmed: 27852235
Dig Dis Sci. 2020 Mar;65(3):741-756
pubmed: 32008133
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48
pubmed: 29462280
Curr HIV/AIDS Rep. 2019 Jun;16(3):204-213
pubmed: 31037552
Nat Med. 2017 Nov;23(11):1271-1276
pubmed: 28967921
Clin Transl Immunology. 2016 Apr 22;5(4):e73
pubmed: 27195116
Gut Microbes. 2017 Sep 3;8(5):440-450
pubmed: 28541799
Pathog Immun. 2019 May 3;4(1):124-146
pubmed: 31139758
Immunity. 2016 May 17;44(5):1005-19
pubmed: 27192566
World J Gastrointest Pathophysiol. 2012 Feb 15;3(1):27-43
pubmed: 22368784
PLoS Pathog. 2019 Apr 4;15(4):e1007611
pubmed: 30947289
EBioMedicine. 2018 Apr;30:192-202
pubmed: 29650491
FEBS Open Bio. 2020 Jan;10(1):41-55
pubmed: 31622538
Nat Rev Microbiol. 2012 Sep;10(9):655-66
pubmed: 22886237
Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G310-9
pubmed: 24284963
J Infect Dis. 2014 Oct 15;210(8):1228-38
pubmed: 24755434
ISME J. 2014 Jun;8(6):1323-35
pubmed: 24553467
PLoS One. 2014 May 20;9(5):e97699
pubmed: 24846174
Gastroenterology. 2015 Jul;149(1):102-109.e6
pubmed: 25857665
Microbiome. 2018 Nov 5;6(1):198
pubmed: 30396369
Mucosal Immunol. 2017 Jul;10(4):996-1007
pubmed: 27848950
Bioinformatics. 2014 Jul 15;30(14):2068-9
pubmed: 24642063
Front Microbiol. 2018 Jun 12;9:1242
pubmed: 29946308